0
     

Report Added
Report already added
Liposomal Doxorubicin Market in India - Manufacturing and Consumption, Outlook and Forecast 2020-2026

Liposomal Doxorubicin Market in India - Manufacturing and Consumption, Outlook and Forecast 2020-2026

Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer._x000D_
_x000D_
This report contains market size and forecasts of Liposomal Doxorubicin in India, including the following market information:_x000D_
India Liposomal Doxorubicin Market Revenue, 2015-2020, 2021-2026, ($ millions)_x000D_
India Liposomal Doxorubicin Market Consumption, 2015-2020, 2021-2026, (K Unit)_x000D_
India Liposomal Doxorubicin Production Capacity, 2015-2020, 2021-2026, (K Unit)_x000D_
Top Five Competitors in India Liposomal Doxorubicin Market 2019 (%)_x000D_
The global Liposomal Doxorubicin market was valued at 1113.3 million in 2019 and is projected to reach US$ 1478 million by 2026, at a CAGR of 7.3% during the forecast period. While the Liposomal Doxorubicin market size in India was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026._x000D_
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Liposomal Doxorubicin manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas._x000D_
This report also analyses and evaluates the COVID-19 impact on Liposomal Doxorubicin production and consumption in India_x000D_
Total Market by Segment:_x000D_
India Liposomal Doxorubicin Market, By Type, 2015-2020, 2021-2026 ($ millions) & (K Unit)_x000D_
India Liposomal Doxorubicin Market Segment Percentages, By Type, 2019 (%)_x000D_
5 ml_x000D_
10 ml_x000D_
25 ml_x000D_
The classification of liposomal doxorubicin includes 5ml, 10 ml, etc. And the proportion of 10ml in 2020 is estimated about 88.77%._x000D_
_x000D_
India Liposomal Doxorubicin Market, By Application, 2015-2020, 2021-2026 ($ millions) & (K Unit)_x000D_
India Liposomal Doxorubicin Market Segment Percentages, By Application, 2019 (%)_x000D_
Breast Cancer_x000D_
Liver Cancer_x000D_
Kidney Cancer_x000D_
Multiple Myeloma_x000D_
Ovarian Cancer_x000D_
Other_x000D_
Liposomal doxorubicin is widely in breast cancer, liver cancer, kidney cancer, multiple myeloma, ovarian cancer, etc. the proportion of breast cancer in 2020 will be about 21.6%._x000D_
_x000D_
Competitor Analysis_x000D_
The report also provides analysis of leading market participants including:_x000D_
Total Liposomal Doxorubicin Market Competitors Revenues in India, by Players 2015-2020 (Estimated), ($ millions)_x000D_
Total Liposomal Doxorubicin Market Competitors Revenues Share in India, by Players 2019 (%)_x000D_
Total India Liposomal Doxorubicin Market Competitors Sales, by Players 2015-2020 (Estimated), (K Unit)_x000D_
Total India Liposomal Doxorubicin Market Competitors Sales Market Share by Players 2019 ($ millions)_x000D_
Further, the report presents profiles of competitors in the market, including the following:_x000D_
Johnson & Johnson_x000D_
Sun Pharmaceutical_x000D_
CSPC_x000D_
Kinyond_x000D_
Teva_x000D_
Fudan-Zhangjiang_x000D_
Zydus Cadila_x000D_
1 Introduction to Research & Analysis Reports_x000D_
1.1 Liposomal Doxorubicin Market Definition_x000D_
1.2 Market Segments_x000D_
1.2.1 Segment by Type_x000D_
1.2.2 Segment by Application_x000D_
1.3 India Liposomal Doxorubicin Market Overview_x000D_
1.4 Features & Benefits of This Report_x000D_
1.5 Methodology & Sources of Information_x000D_
1.5.1 Research Methodology_x000D_
1.5.2 Research Process_x000D_
1.5.3 Base Year_x000D_
1.5.4 Report Assumptions & Caveats_x000D_
_x000D_
2 COVID-19 Impact: India Liposomal Doxorubicin Overall Market Size_x000D_
2.1 India Liposomal Doxorubicin Market Size: 2020 VS 2026_x000D_
2.2 India Liposomal Doxorubicin Revenue, Prospects & Forecasts: 2015-2026_x000D_
2.3 India Liposomal Doxorubicin Sales (Consumption): 2015-2026_x000D_
_x000D_
3 Company Landscape_x000D_
3.1 Top Liposomal Doxorubicin Players in India (including Foreign and Local Companies)_x000D_
3.2 Top India Liposomal Doxorubicin Companies Ranked by Revenue_x000D_
3.3 India Liposomal Doxorubicin Revenue by Companies (including Foreign and Local Companies)_x000D_
3.4 India Liposomal Doxorubicin Sales by Companies (including Foreign and Local Companies)_x000D_
3.5 India Liposomal Doxorubicin Price by Manufacturer (2015-2020)_x000D_
3.6 Top 3 and Top 5 Liposomal Doxorubicin Companies in India, by Revenue in 2019_x000D_
3.7 India Manufacturers Liposomal Doxorubicin Product Type_x000D_
3.8 Tier 1, Tier 2 and Tier 3 Liposomal Doxorubicin Players in India_x000D_
3.8.1 List of India Tier 1 Liposomal Doxorubicin Companies_x000D_
3.8.2 List of India Tier 2 and Tier 3 Liposomal Doxorubicin Companies_x000D_
_x000D_
4 Sights by Product_x000D_
4.1 Overview_x000D_
4.1.1 By Type - India Liposomal Doxorubicin Market Size Markets, 2020 & 2026_x000D_
4.1.2 5 ml_x000D_
4.1.3 10 ml_x000D_
4.1.4 25 ml_x000D_
4.2 By Type - India Liposomal Doxorubicin Revenue & Forecasts_x000D_
4.2.1 By Type - India Liposomal Doxorubicin Revenue, 2015-2020_x000D_
4.2.2 By Type - India Liposomal Doxorubicin Revenue, 2021-2026_x000D_
4.2.3 By Type - India Liposomal Doxorubicin Revenue Market Share, 2015-2026_x000D_
4.3 By Type - India Liposomal Doxorubicin Sales & Forecasts_x000D_
4.3.1 By Type - India Liposomal Doxorubicin Sales, 2015-2020_x000D_
4.3.2 By Type - India Liposomal Doxorubicin Sales, 2021-2026_x000D_
4.3.3 By Type - India Liposomal Doxorubicin Sales Market Share, 2015-2026_x000D_
4.4 By Type - India Liposomal Doxorubicin Price (Manufacturers Selling Prices), 2015-2026_x000D_
5 Sights by Application_x000D_
5.1 Overview_x000D_
5.1.1 By Application - India Liposomal Doxorubicin Market Size, 2020 & 2026_x000D_
5.1.2 Breast Cancer_x000D_
5.1.3 Liver Cancer_x000D_
5.1.4 Kidney Cancer_x000D_
5.1.5 Multiple Myeloma_x000D_
5.1.6 Ovarian Cancer_x000D_
5.1.7 Other_x000D_
5.2 By Application - India Liposomal Doxorubicin Revenue & Forecasts_x000D_
5.2.1 By Application - India Liposomal Doxorubicin Revenue, 2015-2020_x000D_
5.2.2 By Application - India Liposomal Doxorubicin Revenue, 2021-2026_x000D_
5.2.3 By Application - India Liposomal Doxorubicin Revenue Market Share, 2015-2026_x000D_
5.3 By Application - India Liposomal Doxorubicin Sales & Forecasts_x000D_
5.3.1 By Application - India Liposomal Doxorubicin Sales, 2015-2020_x000D_
5.3.2 By Application - India Liposomal Doxorubicin Sales, 2021-2026_x000D_
5.3.3 By Application - India Liposomal Doxorubicin Sales Market Share, 2015-2026_x000D_
5.4 By Application - India Liposomal Doxorubicin Price (Manufacturers Selling Prices), 2015-2026_x000D_
6 Manufacturers & Brands Profiles_x000D_
6.1 Johnson & Johnson_x000D_
6.1.1 Johnson & Johnson Corporate Summary_x000D_
6.1.2 Johnson & Johnson Business Overview_x000D_
6.1.3 Johnson & Johnson Liposomal Doxorubicin Major Product Offerings_x000D_
6.1.4 Johnson & Johnson Sales and Revenue in India (2015-2020)_x000D_
6.1.5 Johnson & Johnson Key News_x000D_
6.2 Sun Pharmaceutical_x000D_
6.2.1 Sun Pharmaceutical Corporate Summary_x000D_
6.2.2 Sun Pharmaceutical Business Overview_x000D_
6.2.3 Sun Pharmaceutical Liposomal Doxorubicin Major Product Offerings_x000D_
6.2.4 Sun Pharmaceutical Sales and Revenue in India (2015-2020)_x000D_
6.2.5 Sun Pharmaceutical Key News_x000D_
6.3 CSPC_x000D_
6.3.1 CSPC Corporate Summary_x000D_
6.3.2 CSPC Business Overview_x000D_
6.3.3 CSPC Liposomal Doxorubicin Major Product Offerings_x000D_
6.3.4 CSPC Sales and Revenue in India (2015-2020)_x000D_
6.3.5 CSPC Key News_x000D_
6.4 Kinyond_x000D_
6.4.1 Kinyond Corporate Summary_x000D_
6.4.2 Kinyond Business Overview_x000D_
6.4.3 Kinyond Liposomal Doxorubicin Major Product Offerings_x000D_
6.4.4 Kinyond Sales and Revenue in India (2015-2020)_x000D_
6.4.5 Kinyond Key News_x000D_
6.5 Teva_x000D_
6.5.1 Teva Corporate Summary_x000D_
6.5.2 Teva Business Overview_x000D_
6.5.3 Teva Liposomal Doxorubicin Major Product Offerings_x000D_
6.5.4 Teva Sales and Revenue in India (2015-2020)_x000D_
6.5.5 Teva Key News_x000D_
6.6 Fudan-Zhangjiang_x000D_
6.6.1 Fudan-Zhangjiang Corporate Summary_x000D_
6.6.2 Fudan-Zhangjiang Business Overview_x000D_
6.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Major Product Offerings_x000D_
6.6.4 Fudan-Zhangjiang Sales and Revenue in India (2015-2020)_x000D_
6.6.5 Fudan-Zhangjiang Key News_x000D_
6.7 Zydus Cadila_x000D_
6.6.1 Zydus Cadila Corporate Summary_x000D_
6.6.2 Zydus Cadila Business Overview_x000D_
6.6.3 Zydus Cadila Liposomal Doxorubicin Major Product Offerings_x000D_
6.4.4 Zydus Cadila Sales and Revenue in India (2015-2020)_x000D_
6.7.5 Zydus Cadila Key News_x000D_
6.8 TTY Biopharma_x000D_
6.8.1 TTY Biopharma Corporate Summary_x000D_
6.8.2 TTY Biopharma Business Overview_x000D_
6.8.3 TTY Biopharma Liposomal Doxorubicin Major Product Offerings_x000D_
6.8.4 TTY Biopharma Sales and Revenue in India (2015-2020)_x000D_
6.8.5 TTY Biopharma Key News_x000D_
_x000D_
7 Liposomal Doxorubicin Production Capacity, Export and Import Analysis_x000D_
7.1 Liposomal Doxorubicin Production Capacity and Value in India, Situation Analysis and Prediction, 2015-2026_x000D_
7.1.1 India Liposomal Doxorubicin Production Capacity, 2015-2026_x000D_
7.1.2 India Liposomal Doxorubicin Production 2015-2026_x000D_
7.1.3 India Liposomal Doxorubicin Production Value 2015-2026_x000D_
7.2 Key Local Liposomal Doxorubicin Manufacturers in India_x000D_
7.2.1 India Key Local Liposomal Doxorubicin Manufacturers Production Capacity_x000D_
7.2.2 India Key Local Liposomal Doxorubicin Manufacturers Production_x000D_
7.2.3 India Key Local Liposomal Doxorubicin Manufacturers Production Value_x000D_
7.2.4 The Proportion of Liposomal Doxorubicin Production Sold in India and Sold Other Than India by Manufacturers_x000D_
7.3 Liposomal Doxorubicin Export and Import in India_x000D_
7.3.1 India Liposomal Doxorubicin Export Market_x000D_
7.3.2 India Liposomal Doxorubicin Source of Imports_x000D_
_x000D_
8 COVID-19 Impact: Key Market Trends, Opportunity, Drivers and Restraints_x000D_
8.1 PESTLE Analysis for India Liposomal Doxorubicin Market_x000D_
8.2 Market Opportunities & Trends_x000D_
8.3 Market Drivers_x000D_
8.4 Market Restraints_x000D_
_x000D_
9 COVID-19 Impact on Liposomal Doxorubicin Supply Chain Analysis_x000D_
9.1 Supply Chain Analysis_x000D_
9.2 Upstream Market Analysis_x000D_
9.3 Downstream and Clients Market Analysis_x000D_
9.4 Marketing Channels Analysis_x000D_
9.4.1 Marketing Channels_x000D_
9.4.2 Liposomal Doxorubicin Distributors and Sales Agents in India_x000D_
_x000D_
10 Conclusion_x000D_
_x000D_
11 Appendix_x000D_
11.1 Note_x000D_
11.2 Examples of Clients_x000D_
11.3 Disclaimer_x000D_
List of Tables_x000D_
Table 1. Key Players of Liposomal Doxorubicin in India_x000D_
Table 2. Top Players in India, Ranking by Revenue (2019)_x000D_
Table 3. India Liposomal Doxorubicin Revenue by Companies, (US$, Mn), 2015-2020_x000D_
Table 4. India Liposomal Doxorubicin Revenue Share by Companies, 2015-2020_x000D_
Table 5. India Liposomal Doxorubicin Sales by Companies, (K Unit), 2015-2020_x000D_
Table 6. India Liposomal Doxorubicin Sales Share by Companies, 2015-2020_x000D_
Table 7. Key Manufacturers Liposomal Doxorubicin Price (2015-2020) (USD/Unit)_x000D_
Table 8. India Manufacturers Liposomal Doxorubicin Product Type_x000D_
Table 9. List of India Tier 1 Liposomal Doxorubicin Companies, Revenue (US$, Mn) in 2019 and Market Share_x000D_
Table 10. List of India Tier 2 and Tier 3 Liposomal Doxorubicin Companies, Revenue (US$, Mn) in 2019 and Market Share_x000D_
Table 11. By Type - Liposomal Doxorubicin Revenue in India (US$, Mn), 2015-2020_x000D_
Table 12. By Type - Liposomal Doxorubicin Revenue in India (US$, Mn), 2021-2026_x000D_
Table 13. By Type - Liposomal Doxorubicin Sales in India (K Unit), 2015-2020_x000D_
Table 14. By Type - Liposomal Doxorubicin Sales in India (K Unit), 2021-2026_x000D_
Table 15. By Application - Liposomal Doxorubicin Revenue in India, (US$, Mn), 2015-2020_x000D_
Table 16. By Application - Liposomal Doxorubicin Revenue in India, (US$, Mn), 2021-2026_x000D_
Table 17. By Application - Liposomal Doxorubicin Sales in India, (K Unit), 2015-2020_x000D_
Table 18. By Application - Liposomal Doxorubicin Sales in India, (K Unit), 2021-2026_x000D_
Table 19. Johnson & Johnson Corporate Summary_x000D_
Table 20. Johnson & Johnson Liposomal Doxorubicin Product Offerings_x000D_
Table 21. Johnson & Johnson Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)_x000D_
Table 22. Sun Pharmaceutical Corporate Summary_x000D_
Table 23. Sun Pharmaceutical Liposomal Doxorubicin Product Offerings_x000D_
Table 24. Sun Pharmaceutical Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)_x000D_
Table 25. CSPC Corporate Summary_x000D_
Table 26. CSPC Liposomal Doxorubicin Product Offerings_x000D_
Table 27. CSPC Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)_x000D_
Table 28. Kinyond Corporate Summary_x000D_
Table 29. Kinyond Liposomal Doxorubicin Product Offerings_x000D_
Table 30. Kinyond Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)_x000D_
Table 31. Teva Corporate Summary_x000D_
Table 32. Teva Liposomal Doxorubicin Product Offerings_x000D_
Table 33. Teva Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)_x000D_
Table 34. Fudan-Zhangjiang Corporate Summary_x000D_
Table 35. Fudan-Zhangjiang Liposomal Doxorubicin Product Offerings_x000D_
Table 36. Fudan-Zhangjiang Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)_x000D_
Table 37. Zydus Cadila Corporate Summary_x000D_
Table 38. Zydus Cadila Liposomal Doxorubicin Product Offerings_x000D_
Table 39. Zydus Cadila Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)_x000D_
Table 40. TTY Biopharma Corporate Summary_x000D_
Table 41. TTY Biopharma Liposomal Doxorubicin Product Offerings_x000D_
Table 42. TTY Biopharma Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)_x000D_
Table 43. Liposomal Doxorubicin Production Capacity (K Unit) of Local Manufacturers in India, 2015-2020_x000D_
Table 44. Liposomal Doxorubicin Production (K Unit) of Local Manufacturers in India, 2015-2020_x000D_
Table 45. India Liposomal Doxorubicin Production Market Share of Local Manufacturers, 2015-2020_x000D_
Table 46. Liposomal Doxorubicin Production Value (US$, Mn) of Local Manufacturers in India, 2015-2020_x000D_
Table 47. India Liposomal Doxorubicin Production Value Market Share of Local Manufacturers, 2015-2020_x000D_
Table 48. The Percentage of Liposomal Doxorubicin Production Sold in India and Sold Other Than India by Manufacturers_x000D_
Table 49. The Percentage of Liposomal Doxorubicin Production Sold in India and Sold Other Than India by Manufacturers_x000D_
Table 50. Dangeguojia Liposomal Doxorubicin Sales (Consumption), Production, Export and Import, 2015-2020_x000D_
Table 51. Raw Materials and Suppliers_x000D_
Table 52. Liposomal Doxorubicin Downstream Clients in India_x000D_
Table 53. Liposomal Doxorubicin Distributors and Sales Agents in India_x000D_
List of Figures_x000D_
Figure 1. Liposomal Doxorubicin Segment by Type_x000D_
Figure 2. Liposomal Doxorubicin Segment by Application_x000D_
Figure 3. Dangeguojia Liposomal Doxorubicin Market Overview: 2020_x000D_
Figure 4. Key Caveats_x000D_
Figure 5. Liposomal Doxorubicin Market Size in India, (US$, Mn) & (K Unit): 2020 VS 2026_x000D_
Figure 6. India Liposomal Doxorubicin Revenue, 2015-2026 (US$, Mn)_x000D_
Figure 7. Liposomal Doxorubicin Sales in India: 2015-2026 (K Unit)_x000D_
Figure 8. The Top 3 and 5 Players Market Share by Liposomal Doxorubicin Revenue in 2019_x000D_
Figure 9. By Type - India Liposomal Doxorubicin Incremental Growth, (US$, Mn), 2015-2026_x000D_
Figure 10. By Type - India Liposomal Doxorubicin Market Share, 2015-2020_x000D_
Figure 11. By Type - India Liposomal Doxorubicin Market Share, 2020-2026_x000D_
Figure 12. By Type - India Liposomal Doxorubicin Price (USD/Unit), 2015-2026_x000D_
Figure 13. By Application - Liposomal Doxorubicin Revenue in India (US$, Mn), 2020 & 2026_x000D_
Figure 14. By Application - India Liposomal Doxorubicin Market Share, 2015-2020_x000D_
Figure 15. By Application - India Liposomal Doxorubicin Market Share, 2020-2026_x000D_
Figure 16. By Application -India Liposomal Doxorubicin Price (USD/Unit), 2015-2026_x000D_
Figure 17. India Liposomal Doxorubicin Production Capacity (K Unit), 2015-2026_x000D_
Figure 18. India Liposomal Doxorubicin Actual Output (K Unit), 2015-2026_x000D_
Figure 19. India Liposomal Doxorubicin Production Value (US$, Mn), 2015-2026_x000D_
Figure 20. The Percentage of India Liposomal Doxorubicin Export Destination, 2019_x000D_
Figure 21. The Source of Imports of India Liposomal Doxorubicin, 2019_x000D_
Figure 22. PEST Analysis for India Liposomal Doxorubicin Market in 2020_x000D_
Figure 23. Liposomal Doxorubicin Market Opportunities & Trends in India_x000D_
Figure 24. Liposomal Doxorubicin Market Drivers in India_x000D_
Figure 25. Liposomal Doxorubicin Market Restraints in India_x000D_
Figure 26. Liposomal Doxorubicin Industry Value Chain_x000D_

Kindly Fill The Form Below

Report Title: Liposomal Doxorubicin Market in India - Manufacturing and Consumption, Outlook and Forecast 2020-2026


Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW